Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this clinical trial is to evaluate safety of switching from
fondaparinux to either unfractionated heparin or bivalirudin for patients experiencing acute
coronary syndrome undergoing percutaneous coronary angioplasty.